Measuring Vaccination Coverage in France: Current Sources and Data
The Act of August 9, 2004, on public health policy entrusts the French Institute for Public Health Surveillance (InVS) with the task of monitoring and evaluating vaccination coverage for all vaccines included in the vaccination schedule and across all target groups. In this study, we first analyzed the various available data sources that can be used to measure vaccination coverage, and second, compiled the most recent national and regional data for the different vaccines and across different age groups. Up to age 15, vaccination coverage is estimated based on children’s health certificates and then on triennial school-based surveys. Among adults, the absence of a routine data collection system explains the lack of data and necessitates the implementation of appropriate tools. Analysis of reimbursement data obtained from the General Practitioner Sample of Beneficiaries (EGB) allows for the provision of data more quickly following changes to the vaccination schedule. Regional and departmental estimates rely primarily on children’s health certificates, but analysis of the comprehensive database of health insurance enrollees (DCIR) should enable more in-depth subnational analyses in the future. The vaccination coverage targets set by the Public Health Act (at least 95% for all vaccinations, except influenza: 75%) are not met for most vaccinations for which vaccination coverage data are available. These data allow recommended vaccinations to be classified into four main groups: vaccinations for which vaccination coverage is high and public health targets have been met (diphtheria, tetanus, polio, pertussis, and Haemophilus influenzae type b in children); those for which coverage is insufficient and stable (HPV in girls, adolescent pertussis booster, MMR first dose, adult DTP 10-year boosters; BCG in at-risk children); those for which coverage is insufficient and declining (seasonal influenza); finally, vaccinations for which coverage is insufficient but increasing (MMR second dose, hepatitis B, meningococcal C, pneumococcal conjugate). (R.A.)
Author(s): Guthmann JP, Fonteneau L, Levy Bruhl D
Publishing year: 2012
Pages: 4 p.
In relation to
Our latest news
news
2026 “Sexual Behavior” Survey (ERAS) for men who have sex with men
news
Hervé Maisonneuve has been appointed scientific integrity officer for a...
news